(0.32%) 5 116.17 points
(0.30%) 38 356 points
(0.37%) 15 987 points
(-0.95%) $83.05
(5.41%) $2.03
(0.36%) $2 355.60
(0.52%) $27.68
(4.25%) $961.30
(-0.27%) $0.932
(-0.44%) $10.98
(-0.58%) $0.796
(1.63%) $93.37
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.31%
@ $887.44
発行日: 29 4月 2024 @ 22:30
リターン: 0.73%
前回のシグナル: 4月 26 - 22:30
前回のシグナル:
リターン: 0.85 %
Live Chart Being Loaded With Signals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion...
Stats | |
---|---|
本日の出来高 | 138 898 |
平均出来高 | 466 048 |
時価総額 | 96.49B |
EPS | $0 ( 2024-02-02 ) |
次の収益日 | ( $10.14 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 25.69 |
ATR14 | $14.57 (1.63%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Ryan Arthur F | Sell | 2 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 2 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 9 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 15 | Common Stock |
2024-04-01 | Ryan Arthur F | Sell | 14 | Common Stock |
INSIDER POWER |
---|
-29.89 |
Last 100 transactions |
Buy: 231 452 | Sell: 428 529 |
ボリューム 相関
Regeneron Pharmaceuticals 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Regeneron Pharmaceuticals 相関 - 通貨/商品
Regeneron Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $13.12B |
総利益: | $11.30B (86.16 %) |
EPS: | $37.05 |
FY | 2023 |
収益: | $13.12B |
総利益: | $11.30B (86.16 %) |
EPS: | $37.05 |
FY | 2022 |
収益: | $12.17B |
総利益: | $10.61B (87.18 %) |
EPS: | $40.51 |
FY | 2021 |
収益: | $16.07B |
総利益: | $13.63B (84.83 %) |
EPS: | $76.40 |
Financial Reports:
Symbol | Period | Year | Title |
---|---|---|---|
REGN | Q4 | 2023 | Financial Report for REGN - Q4 2023 |
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。